Liquidia/$LQDA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Liquidia
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Ticker
$LQDA
Sector
Primary listing
Employees
170
Headquarters
Website
Liquidia Metrics
BasicAdvanced
$2.4B
-
-$1.45
0.51
-
Price and volume
Market cap
$2.4B
Beta
0.51
52-week high
$29.94
52-week low
$9.71
Average daily volume
2.8M
Financial strength
Current ratio
2.202
Quick ratio
1.879
Long term debt to equity
647.12
Total debt to equity
903.238
Interest coverage (TTM)
-5.47%
Profitability
EBITDA (TTM)
-106.044
Gross margin (TTM)
89.11%
Net profit margin (TTM)
-179.28%
Operating margin (TTM)
-154.98%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-25.35%
Return on equity (TTM)
-187.21%
Valuation
Price to revenue (TTM)
34.453
Price to book
109.88
Price to tangible book (TTM)
159.83
Price to free cash flow (TTM)
-22.116
Free cash flow yield (TTM)
-4.52%
Free cash flow per share (TTM)
-1.262
Growth
Revenue change (TTM)
343.41%
Earnings per share change (TTM)
-8.38%
3-year revenue growth (CAGR)
71.22%
3-year earnings per share growth (CAGR)
22.04%
What the Analysts think about Liquidia
Analyst ratings (Buy, Hold, Sell) for Liquidia stock.
Bulls say / Bears say
Liquidia logged more than 900 unique patient prescriptions and over 550 patient starts within 11 weeks of launching YUTREPIA, indicating strong early market penetration and a 75% script-to-start conversion rate. (Investors.com)
Interim results from the ASCENT study showed PH-ILD patients had a median improvement of 31.5 meters in the six-minute walk distance at Week 16, with only an 18.5% drop-out rate and no serious adverse events, highlighting YUTREPIA’s favorable safety and efficacy profile. (Investors.com)
After a U.S. District Court denied United Therapeutics an injunction against YUTREPIA, Liquidia secured a further $50 million under the HCRx financing agreement, strengthening its financial position and supporting the ongoing launch and production expansion. (Nasdaq)
Liquidia’s SG&A expenses almost doubled year-over-year to $38.8 million in Q2 2025, resulting in a net loss of $41.6 million. This raises concerns about high cash burn and challenges to profitability during the commercialization phase. (Reuters)
The $25 million still available under the HCRx agreement depends on YUTREPIA reaching $100 million in net sales by June 30, 2026; this introduces execution risk and the potential for a funding shortfall if sales momentum slows. (Investing.com)
Other expenses increased to $4.1 million in Q2 2025 from $1.5 million a year ago, mainly due to more borrowing under the HCR Agreement, which points to increased interest and financing costs weighing on the balance sheet. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
Liquidia Financial Performance
Revenues and expenses
Liquidia Earnings Performance
Company profitability
Liquidia News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Liquidia stock?
Liquidia (LQDA) has a market cap of $2.4B as of November 06, 2025.
What is the P/E ratio for Liquidia stock?
The price to earnings (P/E) ratio for Liquidia (LQDA) stock is 0 as of November 06, 2025.
Does Liquidia stock pay dividends?
No, Liquidia (LQDA) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Liquidia dividend payment date?
Liquidia (LQDA) stock does not pay dividends to its shareholders.
What is the beta indicator for Liquidia?
Liquidia (LQDA) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.